Latin America Continuous Glucose Monitoring Device had a measurement inaccuracy of more than 20% when it first became commercially available in the year 2000. 1 Overall measurement error has been reduced by a factor of two in recent years, and accuracy continues to improve. CGM sensors/devices have shrunk in size, weight, complexity, and cost, while their duration of use, specificity, user-friendliness, user interface and displays, data management, and software for data analysis have all improved. Clinical advantages have been established in a variety of patient categories, including paediatrics, adolescents, and adults, with varying levels of glycemic control at baseline. The benefit is proportionate to how often you use it. The effectiveness of CGM can work in tandem with the advantages of insulin pumps.
Read More:
Click here for Latin America Continuous Glucose Monitoring Device Market Report:
Click here for Latin America Continuous Glucose Monitoring Device Market Press Release: